PATENT CLAIM ANALYSIS

Application Number: 15921518
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-09
Patent Classification: ["514", "044000"]

Abstract:
The invention relates to the use of an antisense compound for inducing exon inclusion as a treatment for Spinal Muscle Atrophy (SMA). More particularly it relates to inducing inclusion of exon 7 to restore levels of Survival Motor Neuron (SMN) protein encoded by the Survival Motor Neuron (SMN) gene.

Claim (Index 20):
The antisense oligonucleotide of  claim 18 , wherein the sequence is complementary to a portion of intron 7 and exon 8 of the SMN2 pre-mRNA.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 90.0
- Lexical Diversity: 1.5
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14360895', '14647952', '14360890', '14134057', '14443367']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8039481498346736
- 35 USC 102 Novelty (BERT): 0.5824569596890459
- Combined Prediction Score: 0.7817990308201108
- Mean Citation Score: 384.646352
- Max Citation Score: 509.5931
- Similarity Product: 394.78601980220674

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test